Dr Marco Siccardi PhD
Reader Pharmacology & Therapeutics
- Work email M.Siccardi@liverpool.ac.uk
- Personal Websitehttps://www.researchgate.net/profile/Marco_Siccardi
Publications
Filter the publication list
Filter list by type
- Show all
- Journal article
- Conference paper
- Chapter
- Other
2022
Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling (Journal article)
Granana-Castillo, S., Montanha, M. C., Bearon, R., Khoo, S., & Siccardi, M. (2022). Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling. FRONTIERS IN PHARMACOLOGY, 13. doi:10.3389/fphar.2022.1076266The LEAP Process: Streamlining the Development of Long-Acting Products and Formulations for Infectious Diseases. (Journal article)
Flexner, C., Siccardi, M., Bunglawala, F., & Owen, A. (2022). The LEAP Process: Streamlining the Development of Long-Acting Products and Formulations for Infectious Diseases.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 75(Suppl 4), S502-S509. doi:10.1093/cid/ciac750Evaluating Islatravir Administered Via Microneedle Array Patch for Long-Acting HIV Pre-exposure Prophylaxis Using Physiologically Based Pharmacokinetic Modelling (Journal article)
Kinvig, H., Cottura, N., Lloyd, A., Frivold, C., Mistilis, J., Jarrahian, C., & Siccardi, M. (2022). Evaluating Islatravir Administered Via Microneedle Array Patch for Long-Acting HIV Pre-exposure Prophylaxis Using Physiologically Based Pharmacokinetic Modelling. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 47(6), 855-868. doi:10.1007/s13318-022-00793-6Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling (vol 61, pg 375, 2022) (Journal article)
Montanha, M. C., Fabrega, F., Howarth, A., Cottura, N., Kinvig, H., Bunglawala, F., . . . Siccardi, M. (2022). Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling (vol 61, pg 375, 2022). CLINICAL PHARMACOKINETICS, 61(11), 1641. doi:10.1007/s40262-022-01178-3Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine- or darunavir-based antiretroviral therapy (Journal article)
Nakalema, S., Chappell, C. A., Pham, M., Byakika-Kibwika, P., Kaboggoza, J., Walimbwa, S. I., . . . Lamorde, M. (2022). Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine- or darunavir-based antiretroviral therapy. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(11), 3144-3152. doi:10.1093/jac/dkac296A physiologically based pharmacokinetic model to predict pegylated liposomal doxorubicin disposition in rats and human (Journal article)
Montanha, M. C., Howarth, A., Mohamed, D. A., Loier, E., Main, L., Rosslein, M., . . . Siccardi, M. (2022). A physiologically based pharmacokinetic model to predict pegylated liposomal doxorubicin disposition in rats and human. DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 12(9), 2178-2186. doi:10.1007/s13346-022-01175-wDrug-Drug Interactions in People Living With HIV at Risk of Hepatic and Renal Impairment: Current Status and Future Perspectives (Journal article)
Cottura, N., Kinvig, H., Granana-Castillo, S., Wood, A., & Siccardi, M. (2022). Drug-Drug Interactions in People Living With HIV at Risk of Hepatic and Renal Impairment: Current Status and Future Perspectives. JOURNAL OF CLINICAL PHARMACOLOGY, 62(7), 835-846. doi:10.1002/jcph.2025PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease (Journal article)
Montanha, M. C., Cottura, N., Booth, M., Hodge, D., Bunglawala, F., Kinvig, H., . . . Siccardi, M. (2022). PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease. FRONTIERS IN PHARMACOLOGY, 13. doi:10.3389/fphar.2022.814134Evaluating Islatravir Administered Via Microneedle Array Patch for Long-Acting HIV Pre-exposure Prophylaxis Using Physiologically Based Pharmacokinetic Modelling (vol 47, pg 855, 2022) (Journal article)
Kinvig, H., Cottura, N., Lloyd, A., Frivold, C., Mistilis, J., Jarrahian, C., & Siccardi, M. (2023). Evaluating Islatravir Administered Via Microneedle Array Patch for Long-Acting HIV Pre-exposure Prophylaxis Using Physiologically Based Pharmacokinetic Modelling (vol 47, pg 855, 2022). EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 48(1), 119. doi:10.1007/s13318-022-00811-72021
Evaluating the impact of systematic hydrophobic modification of model drugs on the control, stability and loading of lipid-based nanoparticles (Journal article)
Hogarth, C., Arnold, K., McLauchlin, A., Rannard, S. P., Siccardi, M., & McDonald, T. O. (2021). Evaluating the impact of systematic hydrophobic modification of model drugs on the control, stability and loading of lipid-based nanoparticles. JOURNAL OF MATERIALS CHEMISTRY B, 9(48), 9874-9884. doi:10.1039/d1tb02297kPhysiologically based pharmacokinetic modeling for dose optimization of quinine-phenobarbital coadministration in patients with cerebral malaria (Journal article)
Sae-Heng, T., Rajoli, R. K. R., Siccardi, M., Karbwang, J., & Na-Bangchang, K. (2021). Physiologically based pharmacokinetic modeling for dose optimization of quinine-phenobarbital coadministration in patients with cerebral malaria. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 11(1), 104-115. doi:10.1002/psp4.12737In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel (Journal article)
Roberts, O., Kinvig, H., Owen, A., Lamorde, M., Siccardi, M., & Scarsi, K. K. (2021). In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel. HIV MEDICINE, 22(10), 898-906. doi:10.1111/hiv.13136Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling (Journal article)
Montanha, M. C., Fabrega, F., Howarth, A., Cottura, N., Kinvig, H., Bunglawala, F., . . . Siccardi, M. (2021). Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling. CLINICAL PHARMACOKINETICS. doi:10.1007/s40262-021-01067-1Methodological needs in the quality and safety characterisation of nanotechnology-based health products: Priorities for method development and standardisation (Journal article)
Halamoda-Kenzaoui, B., Vandebriel, R. J., Howarth, A., Siccardi, M., David, C. A. W., Liptrott, N. J., . . . Caputo, F. (2021). Methodological needs in the quality and safety characterisation of nanotechnology-based health products: Priorities for method development and standardisation. JOURNAL OF CONTROLLED RELEASE, 336, 192-206. doi:10.1016/j.jconrel.2021.06.016Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment (Journal article)
Marra, F., Smolders, E. J., El-Sherif, O., Boyle, A., Davidson, K., Sommerville, A. J., . . . Back, D. (2021). Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. DRUGS IN R&D, 21(1), 9-27. doi:10.1007/s40268-020-00333-0Clinical Data Combined With Modeling and Simulation Indicate Unchanged Drug-Drug Interaction Magnitudes in the Elderly (Journal article)
Stader, F., Courlet, P., Kinvig, H., Penny, M. A., Decosterd, L. A., Battegay, M., . . . Marzolini, C. (2021). Clinical Data Combined With Modeling and Simulation Indicate Unchanged Drug-Drug Interaction Magnitudes in the Elderly. CLINICAL PHARMACOLOGY & THERAPEUTICS, 109(2), 471-484. doi:10.1002/cpt.2017Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation (Journal article)
Stader, F., Courlet, P., Kinvig, H., Battegay, M., Decosterd, L. A., Penny, M. A., . . . Marzolini, C. (2021). Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(2), 458-470. doi:10.1111/bcp.14402Long-acting drugs and formulations for the treatment and prevention of HIV infection (Journal article)
Flexner, C., Owen, A., Siccardi, M., & Swindells, S. (2021). Long-acting drugs and formulations for the treatment and prevention of HIV infection. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 57(1). doi:10.1016/j.ijantimicag.2020.1062202020
Drug interactions: a review of the unseen danger of experimental COVID-19 therapies (Journal article)
Hodge, C., Marra, F., Marzolini, C., Boyle, A., Gibbons, S., Siccardi, M., . . . Khoo, S. (2020). Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(12), 3417-3424. doi:10.1093/jac/dkaa340The Current Landscape of Novel Formulations and the Role of Mathematical Modeling in Their Development (Journal article)
Cottura, N., Howarth, A., Rajoli, R. K. R., & Siccardi, M. (2020). The Current Landscape of Novel Formulations and the Role of Mathematical Modeling in Their Development. JOURNAL OF CLINICAL PHARMACOLOGY, 60, S77-S97. doi:10.1002/jcph.1715The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics (Journal article)
Siccardi, M., Schapiro, J., Di Perri, G., & Back, D. J. (2020). The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(9), 2381-2383. doi:10.1093/jac/dkaa272Predicting pharmacokinetics of a tenofovir alafenamide subcutaneous implant using PBPK modelling. (Journal article)
Rajoli, R. K. R., Demkovich, Z. R., Flexner, C., Owen, A., & Siccardi, M. (2020). Predicting pharmacokinetics of a tenofovir alafenamide subcutaneous implant using PBPK modelling.. Antimicrobial Agents and Chemotherapy. doi:10.1128/aac.00155-20Physiologically-Based Pharmacokinetic Modeling for Optimal Dosage Prediction of Quinine Coadministered With Ritonavir-Boosted Lopinavir (Journal article)
Saeheng, T., Na-Bangchang, K., Siccardi, M., Rajoli, R. K. R., & Karbwang, J. (2020). Physiologically-Based Pharmacokinetic Modeling for Optimal Dosage Prediction of Quinine Coadministered With Ritonavir-Boosted Lopinavir. CLINICAL PHARMACOLOGY & THERAPEUTICS, 107(5), 1209-1220. doi:10.1002/cpt.1721Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly (Journal article)
Stader, F., Kinvig, H., Penny, M. A., Battegay, M., Siccardi, M., & Marzolini, C. (2020). Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly. CLINICAL PHARMACOKINETICS, 59(3), 383-401. doi:10.1007/s40262-019-00822-9Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling (Journal article)
Bunglawala, F., Rajoli, R. K. R., Mirochnick, M., Owen, A., & Siccardi, M. (2020). Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(3), 640-647. doi:10.1093/jac/dkz506Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz (Journal article)
Adegbola, A. J., Rana, A., Adeagbo, B. A., Bolarinwa, R. A., Olagunju, A. E., Siccardi, M., . . . Bolaji, O. O. (2020). Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz. PHARMACOGENETICS AND GENOMICS, 30(5), 96-106. doi:10.1097/FPC.00000000000004012019
Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies (Journal article)
Atoyebi, S. A., Rajoli, R. K. R., Adejuyigbe, E., Owen, A., Bolaji, O., Siccardi, M., & Olagunju, A. (2019). Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 140. doi:10.1016/j.ejps.2019.105068Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulations (Journal article)
Hobson, J. J., Curley, P., Savage, A. C., Al-khouja, A., Siccardi, M., Flexner, C., . . . Rannard, S. P. (2019). Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulations. NANOSCALE ADVANCES, 1(11), 4301-4307. doi:10.1039/c9na00529cModelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK (Journal article)
Rajoli, R. K. R., Flexner, C., Chiong, J., Owen, A., Donnelly, R. F., Larraneta, E., & Siccardi, M. (2019). Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 144, 101-109. doi:10.1016/j.ejpb.2019.09.011Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART (Journal article)
Neary, M., Chappell, C. A., Scarsi, K. K., Nakalema, S., Matovu, J., Achilles, S. L., . . . Lamorde, M. (2019). Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(10), 3003-3010. doi:10.1093/jac/dkz298Effect of CYP2B6 Metabolizer Status on Levonorgestrel Pharmacokinetics When Combined with Efavirenz-based Antiretroviral Therapy (Conference Paper)
Pham, M., Mbabzi, O., Neary, M. G., Nakalema, S., Campbell, K., Cirrincione, L., . . . Kimberly, S. (2019). Effect of CYP2B6 Metabolizer Status on Levonorgestrel Pharmacokinetics When Combined with Efavirenz-based Antiretroviral Therapy. In PK workshop. Amsterdam, Netherlands.Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling (Journal article)
Rajoli, R. K. R., Curley, P., Chiong, J., Back, D., Flexner, C., Owen, A., & Siccardi, M. (2019). Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling. JOURNAL OF INFECTIOUS DISEASES, 219(11), 1735-1742. doi:10.1093/infdis/jiy726Improving maraviroc oral bioavailability by formation of solid drug nanoparticles (Journal article)
Savage, A. C., Tatham, L. M., Siccardi, M., Scott, T., Vourvahis, M., Clark, A., . . . Owen, A. (2019). Improving maraviroc oral bioavailability by formation of solid drug nanoparticles. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 138, 30-36. doi:10.1016/j.ejpb.2018.05.015Towards a Maraviroc long-acting injectable nanoformulation (Journal article)
Tatham, L. M., Savage, A. C., Dwyer, A., Siccardi, M., Scott, T., Vourvahis, M., . . . Owen, A. (2019). Towards a Maraviroc long-acting injectable nanoformulation. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 138, 92-98. doi:10.1016/j.ejpb.2018.04.009Effect of tenofovir and abacavir on dolutegravir transport in vitro and in vivo (Conference Paper)
Neary, M. G., Tatham, L., Sharp, J., Ayuso, P., Abutaima, R., Box, H., . . . Owen, A. (2019, May 14). Effect of tenofovir and abacavir on dolutegravir transport in vitro and in vivo. In 20th International Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs.. Hotel Oranje, Noordwijk, NL.Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes (Journal article)
Stader, F., Siccardi, M., Battegay, M., Kinvig, H., Penny, M. A., & Marzolini, C. (2019). Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes. CLINICAL PHARMACOKINETICS, 58(4), 483-501. doi:10.1007/s40262-018-0709-7Semi-solid pro-drug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs for combination HIV therapies (Conference Paper)
Hobson, J., Al-Khouja, A., Curley, P., Flexner, C., Meyers, C., Owen, A., & Rannard, S. (2017). Semi-solid pro-drug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs for combination HIV therapies. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. Retrieved from https://www.webofscience.com/Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies (Journal article)
Hobson, J., Al-Khouja, A., Curley, P., Meyers, D., Flexner, C., Siccardi, M., . . . Rannard, S. P. (2019). Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies. Nature Communications, 10. doi:10.1038/s41467-019-09354-zImpact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics (Journal article)
Gini, J., Olagunju, A., Dickinson, L., Waitt, C., Neary, M., Else, L. J., . . . Khoo, S. (2019). Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics. PHARMACOGENOMICS, 20(4), 217-224. doi:10.2217/pgs-2018-0111A comprehensive framework for physiologically based pharmacokinetic modelling in Matlab®. (Journal article)
Stader, F., Penny, M. A., Siccardi, M., & Marzolini, C. (2019). A comprehensive framework for physiologically based pharmacokinetic modelling in Matlab®.. CPT: pharmacometrics & systems pharmacology. doi:10.1002/psp4.123992018
Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro (Journal article)
Gurjar, R., Chan, C. Y. S., Curley, P., Sharp, J., Chiong, J., Rannard, S., . . . Owen, A. (2018). Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro. MOLECULAR PHARMACEUTICS, 15(11), 4835-4842. doi:10.1021/acs.molpharmaceut.8b00482Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection (Journal article)
Adegbola, A., Abutaima, R., Olagunju, A., Ijarotimi, O., Siccardi, M., Owen, A., . . . Bolaji, O. (2018). Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(10). doi:10.1128/AAC.01252-18Derivation of CYP3A4 and CYP2B6 degradation rate constants in primary human hepatocytes: A siRNA-silencing-based approach (Journal article)
Chan, C. Y. S., Roberts, O., Rajoli, R. K. R., Liptrott, N. J., Siccardi, M., Almond, L., & Owen, A. (2018). Derivation of CYP3A4 and CYP2B6 degradation rate constants in primary human hepatocytes: A siRNA-silencing-based approach. DRUG METABOLISM AND PHARMACOKINETICS, 33(4), 179-187. doi:10.1016/j.dmpk.2018.01.004Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study (Journal article)
Rajoli, R. K. R., Podany, A. T., Moss, D. M., Swindells, S., Flexner, C., Owen, A., & Siccardi, M. (2018). Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 22(8), 937-944. doi:10.5588/ijtld.17.0515Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications (Journal article)
Stader, F., Kinvig, H., Battegay, M., Khoo, S., Owen, A., Siccardi, M., & Marzolini, C. (2018). Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(7). doi:10.1128/AAC.00717-18The emerging role of physiologically based pharmacokinetic modelling in solid drug nanoparticle translation (Journal article)
Siccardi, M., Rannard, S., & Owen, A. (2018). The emerging role of physiologically based pharmacokinetic modelling in solid drug nanoparticle translation. Advanced Drug Delivery Reviews, 131, 116-121. doi:10.1016/j.addr.2018.06.016Improved Oral In Vivo Pharmacokinetics of Novel Oil in Water Solid Drug Nanoparticle formulations of Tenofovir Disoproxil Fumarate for the treatment of HIV (Conference Paper)
Curley, P., Hobson, J., David, C., Box, H., Neary, M. G., Sharp, J., . . . Owen, A. (n.d.). Improved Oral In Vivo Pharmacokinetics of Novel Oil in Water Solid Drug Nanoparticle formulations of Tenofovir Disoproxil Fumarate for the treatment of HIV. In CLINAM European Foundation for Clinical Nanomedicine.Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding (Journal article)
Olagunju, A., Rajoli, R. K. R., Atoyebi, S. A., Khoo, S., Owen, A., & Siccardi, M. (2018). Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding. AAS Open Research, 1(16). doi:10.12688/aasopenres.12860.1Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma (Journal article)
Cirrincione, L. R., Penchala, S. D., Scarsi, K. K., Podany, A. T., Winchester, L. C., Back, D. J., . . . Else, L. J. (2018). Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1084, 106-112. doi:10.1016/j.jchromb.2018.03.023Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug–drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART (Journal article)
Roberts, O., Rajoli, R. K. R., Back, D. J., Owen, A., Darin, K. M., Fletcher, C. V., . . . Siccardi, M. (2018). Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug–drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART. Journal of Antimicrobial Chemotherapy, 73(4), 1004-1012. doi:10.1093/jac/dkx515Maraviroc solid drug nanoparticles with improved oral pharmacokinetics (Conference Paper)
Tatham, L., Savage, A. C., Dwyer, A. B., Siccardi, M., Scott, T., Vourvahis, M., . . . Owen, A. (2018). Maraviroc solid drug nanoparticles with improved oral pharmacokinetics. In CROI. Boston MA.Towards a Long-Acting Injectable (LAI) Formulation For Maraviroc (Conference Paper)
Tatham, L., Dwyer, A. B., Savage, A. C., Siccardi, M., Scott, T., Vourvahis, M., . . . Owen, A. (2018). Towards a Long-Acting Injectable (LAI) Formulation For Maraviroc. In CROI. Boston MA.CYP2B6 variants alter etonogestrel pharmacokinetics when combined with efavirenz. (Conference Paper)
Neary, M. G., Chappell, C., Scarsi, K., Nakalema, S., Matovu, J., Achilles, S., . . . Lamorde, M. (2018, March 5). CYP2B6 variants alter etonogestrel pharmacokinetics when combined with efavirenz.. In CROI. Boston, MA, USA.In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents. (Journal article)
Rajoli, R. K. R., Back, D. J., Rannard, S., Meyers, C. F., Flexner, C., Owen, A., & Siccardi, M. (2018). In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.. Clinical pharmacokinetics, 57(02), 255-266. doi:10.1007/s40262-017-0557-xLong-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges (Journal article)
Swindells, S., Siccardi, M., Barrett, S. E., Olsen, D. B., Grobler, J. A., Podany, A. T., . . . Flexner, C. (2018). Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 22(2), 125-132. doi:10.5588/ijtld.17.0486Development of Prodrug Approaches for Long-Acting Nanoformulations of Emtricitabine-Based Regimens (Conference Paper)
Al-Khouja, A., Hobson, J. J., Henriquez, S., Meyers, D., Curley, P., Siccardi, M., . . . Meyers, C. L. F. (2018). Development of Prodrug Approaches for Long-Acting Nanoformulations of Emtricitabine-Based Regimens. In FASEB JOURNAL Vol. 32. Retrieved from https://www.webofscience.com/Solid drug nanoparticles synthesised using spontaneous nanoprecipitation of tenofovir disoproxil fumerate: From proof of concept to in vivo pharmacokinetics of improved oral dosage (Conference Paper)
Hobson, J., Curley, P., Al-khouja, A., Siccardi, M., Flexner, C., Meyers, C., . . . Rannard, S. (2018). Solid drug nanoparticles synthesised using spontaneous nanoprecipitation of tenofovir disoproxil fumerate: From proof of concept to in vivo pharmacokinetics of improved oral dosage. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 256. Retrieved from https://www.webofscience.com/2017
Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates (Journal article)
Chan, C., Martin, P., Liptrott, N. J., Siccardi, M., Almond, L., & Owen, A. (2017). Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates. PHARMACOLOGY RESEARCH & PERSPECTIVES, 5(5). doi:10.1002/prp2.359The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine (Journal article)
Neary, M., Lamorde, M., Olagunju, A., Darin, K. M., Merry, C., Byakika-Kibwika, P., . . . Scarsi, K. K. (2017). The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine. CLINICAL PHARMACOLOGY & THERAPEUTICS, 102(3), 529-536. doi:10.1002/cpt.667Dual-stimuli responsive injectable nanogel/solid drug nanoparticle nanocomposites for release of poorly soluble drugs (Conference Paper)
Town, A., Gurjar, R., Giardiello, M., Briggs, M., Akhtar, R., Siccardi, M., & McDonald, T. (2017). Dual-stimuli responsive injectable nanogel/solid drug nanoparticle nanocomposites for release of poorly soluble drugs. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. doi:10.1039/C6NR07858CTransdermal delivery with microneedle patches using in silico modelling (Presentation material)
Rajoli, R. K. R., Flexner, C., Owen, A., Donnelly, R., & Siccardi, M. (2017). Transdermal delivery with microneedle patches using in silico modelling. Belfast.Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate (Journal article)
Moss, D. M., Domanico, P., Watkins, M., Park, S., Randolph, R., Wring, S., . . . Owen, A. (2017). Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(7). doi:10.1128/AAC.00105-17Dual-stimuli responsive injectable microgel/solid drug nanoparticle nanocomposites for release of poorly soluble drugs (Journal article)
Town, A. R., Giardiello, M., Gurjar, R., Siccardi, M., Briggs, M. E., Akhtar, R., & McDonald, T. O. (2017). Dual-stimuli responsive injectable microgel/solid drug nanoparticle nanocomposites for release of poorly soluble drugs. Nanoscale, 9(19), 6302-6314. doi:10.1039/c6nr07858cInteraction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro (Journal article)
Roberts, O., Khoo, S., Owen, A., & Siccardi, M. (2017). Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(5). doi:10.1128/AAC.01776-16Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes (Journal article)
Marzolini, C., Rajoli, R., Battegay, M., Elzi, L., Back, D., & Siccardi, M. (2017). Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. CLINICAL PHARMACOKINETICS, 56(4), 409-420. doi:10.1007/s40262-016-0447-7Use of a physiologically based pharmacokinetic model to simulate drug–drug interactions between antineoplastic and antiretroviral drugs (Journal article)
Molto, J., Rajoli, R., Back, D. J., Valle, M., Miranda, C., Owen, A., . . . Siccardi, M. (2017). Use of a physiologically based pharmacokinetic model to simulate drug–drug interactions between antineoplastic and antiretroviral drugs. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(3), 805-811. doi:10.1093/jac/dkw485A physiologically based pharmacokinetic model to predict the superparamagnetic iron oxide nanoparticles (SPIONs) accumulation in vivo (Journal article)
Silva, A. H., Lima, E. J., Mansilla, M. V., Zysler, R. D., Mojica Pisciotti, M. L., Locatelli, C., . . . Siccardi, M. (2017). A physiologically based pharmacokinetic model to predict the superparamagnetic iron oxide nanoparticles (SPIONs) accumulation in vivo. EUROPEAN JOURNAL OF NANOMEDICINE, 9(2), 79-90. doi:10.1515/ejnm-2017-0001Development of prodrug approaches for long-acting nanoformulations of emtricitabine-based regimens (Conference Paper)
Al-Khouja, A., Hobson, J., Meyers, D., Curley, P., Siliciano, J., Siliciano, R., . . . Meyers, C. (2017). Development of prodrug approaches for long-acting nanoformulations of emtricitabine-based regimens. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. Retrieved from https://www.webofscience.com/Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation (Journal article)
Curley, P., Rajoli, R. K. R., Moss, D. M., Liptrott, N. J., Letendre, S., Owen, A., & Siccardi, M. (2017). Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(1). doi:10.1128/AAC.01841-16Integrated pharmacokinetic modelling for accelerated nanomedicine translation (Journal article)
Siccardi, M., Löffler, B., Balogh, L., & Owen, A. (2017). Integrated pharmacokinetic modelling for accelerated nanomedicine translation. European Journal of Nanomedicine, 9(1), 1-3. doi:10.1515/ejnm-2016-0041Six year manufacturing to human clinical trial programme for the first oral dosed HIV nanomedicines (Conference Paper)
Giardiello, M., McDonald, T., Liptrott, N., Martin, P., Smith, D., Siccardi, M., . . . Rannard, S. (2017). Six year manufacturing to human clinical trial programme for the first oral dosed HIV nanomedicines. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 254. Retrieved from https://www.webofscience.com/USE OF MRNA SUPPRESSION TO ESTIMATE CYP3A4 PROTEIN DEGRADATION RATE CONSTANT IN PRIMARY HUMAN HEPATOCYTES (Conference Paper)
Chan, C. Y., Roberts, O., Hassan, N., Liptrott, N., Siccardi, M., Almond, L., & Owen, A. (2017). USE OF MRNA SUPPRESSION TO ESTIMATE CYP3A4 PROTEIN DEGRADATION RATE CONSTANT IN PRIMARY HUMAN HEPATOCYTES. In DRUG METABOLISM AND PHARMACOKINETICS Vol. 32 (pp. S109). doi:10.1016/j.dmpk.2016.10.0992016
Computational Predictive Models for Nanomedicine (Chapter)
Siccardi, M., Schipani, A., & Owen, A. (n.d.). Computational Predictive Models for Nanomedicine. In Pharmaceutical Nanotechnology: Innovation and Production: Innovation and Production (pp. 379-402). Wiley-VCH Verlag GmbH & Co. KGaA.Simulation of long-acting administration of antituberculosis agents using pharmacokinetic modelling (Presentation material)
Rajoli, R. K. R., Podany, A., Swindells, S., Flexner, C., Owen, A., & Siccardi, M. (2016). Simulation of long-acting administration of antituberculosis agents using pharmacokinetic modelling. Liverpool.Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies (Journal article)
Giardiello, M., Liptrott, M. J., McDonald, T. O., Moss, D., Siccardi, M., Martin, P., . . . Owen, A. (2016). Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies. Nature Communications, 7. doi:10.1038/ncomms13184Development and validation of an LC-MS/MS assay for the quantification of efavirenz in different biological matrices (Journal article)
Curley, P., Siccardi, M., Moss, D. M., & Owen, A. (2016). Development and validation of an LC-MS/MS assay for the quantification of efavirenz in different biological matrices. BIOANALYSIS, 8(20), 2125-2134. doi:10.4155/bio-2016-0021Towards a rational design of solid drug nanoparticles with optimised pharmacological properties. (Journal article)
Siccardi, M., Martin, P., Smith, D., Curley, P., McDonald, T., Giardiello, M., . . . Owen, A. (2016). Towards a rational design of solid drug nanoparticles with optimised pharmacological properties.. Journal of interdisciplinary nanomedicine, 1(3), 110-123. doi:10.1002/jin2.21Long-acting injectable formulations for children and adolescents using PBPK modelling (Presentation material)
Rajoli, R. K. R., Back, D., Rannard, S., Flexner, C., Owen, A., & Siccardi, M. (2016). Long-acting injectable formulations for children and adolescents using PBPK modelling. Swansea.Validation of computational approaches for antiretroviral dose optimization (Journal article)
Siccardi, M., Dickinson, L., & Owen, A. (n.d.). Validation of computational approaches for antiretroviral dose optimization. Antimicrobial Agents and Chemotherapy, 60, 3838-3839. doi:10.1128/AAC.00094-16Validation of Computational Approaches for Antiretroviral Dose Optimization (vol 60, pg 3838, 2016) (Journal article)
Siccardi, M., Dickinson, L., & Owen, A. (2016). Validation of Computational Approaches for Antiretroviral Dose Optimization (vol 60, pg 3838, 2016). ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(1). Retrieved from http://gateway.webofknowledge.com/Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach (Journal article)
Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2016). Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(4), 1041-1045. doi:10.1093/jac/dkv439Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models (Poster)
Rajoli, R. K. R., Back, D., Rannard, S., Owen, A., & Siccardi, M. (2016). Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models. Poster session presented at the meeting of Conference on Retroviral and Opportunistic Infections. Boston, MA, USA.Effect of CYP2B6 variants on levonorgestrel pharmacokinetics when combined with efavirenz based antiretroviral therapy. (Conference Paper)
Neary, M. G., Lamorde, M., Olagunju, A., Darin, K., Merry, C., Byakika-Kibwika, P., . . . Scarsi, K. (n.d.). Effect of CYP2B6 variants on levonorgestrel pharmacokinetics when combined with efavirenz based antiretroviral therapy.. In CROI. Boston, MA, USA.Interaction of Darunavir/Ritonavir and Darunavir/Cobicistat With Rifampicin In Vitro (Conference Paper)
Roberts, O., Back, D., Khoo, S., Owen, A., & Siccardi, M. (2016). Interaction of Darunavir/Ritonavir and Darunavir/Cobicistat With Rifampicin In Vitro. In CROI. Boston, USA.2015
Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV (Journal article)
Rajoli, R. K. R., Back, D. J., Rannard, S., Meyers, C. L. F., Flexner, C., Owen, A., & Siccardi, M. (2015). Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV. CLINICAL PHARMACOKINETICS, 54(6), 639-650. doi:10.1007/s40262-014-0227-1Prediction of Infant Exposure to Maternal Drugs From Breast Milk Using PBPK Modeling (Conference Paper)
Olagunju, A., Rajoli, R., Bolaji, O., Back, D., Khoo, S., Owen, A., & Siccardi, M. (2016, February 21). Prediction of Infant Exposure to Maternal Drugs From Breast Milk Using PBPK Modeling. In CROI.Prevalence and type of drug-drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda (Journal article)
Seden, K., Merry, C., Hewson, R., Siccardi, M., Lamorde, M., Byakika-Kibwika, P., . . . Khoo, S. H. (2015). Prevalence and type of drug-drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(12), 3317-3322. doi:10.1093/jac/dkv259Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models (Conference Paper)
Rajoli, R. K. R., Siccardi, M., Owen, A., Back, D., & Rannard, S. (2016, February 22). Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models. In Conference on Retroviral and Opportunistic Infections. Boston, MA. Retrieved from http://www.croiconference.org/Class-specific relative genetic contribution for key antiretroviral drugs (Journal article)
Siccardi, M., Olagunju, A., Simiele, M., D'Avolio, A., Calcagno, A., Di Perri, G., . . . Owen, A. (2015). Class-specific relative genetic contribution for key antiretroviral drugs. Journal of Antimicrobial Chemotherapy, 70(11), 3074-3079. doi:10.1093/jac/dkv207Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study) (Journal article)
Bonora, S., Rusconi, S., Calcagno, A., Bracchi, M., Vigano, O., Cusato, J., . . . Di Perri, G. (2015). Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(11), 3096-3099. doi:10.1093/jac/dkv208Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles (Journal article)
Martin, P., Giardiello, M., McDonald, T. C., Smith, D., Siccardi, M., Rannard, S. P., & Owen, A. (2015). Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles. MOLECULAR PHARMACEUTICS, 12(10), 3556-3568. doi:10.1021/acs.molpharmaceut.5b00204Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots (Journal article)
Olagunju, A., Amara, A., Waitt, C., Else, L., Penchala, S. D., Bolaji, O., . . . Khoo, S. (2015). Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(10), 2816-2822. doi:10.1093/jac/dkv174Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies (Journal article)
Moss, D. M., Marzolini, C., Rajoli, R. K. R., & Siccardit, M. (2015). Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 11(8), 1203-1217. doi:10.1517/17425255.2015.1037278Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study (Journal article)
Olagunju, A., Bolaji, O., Amara, A., Waitt, C., Else, L., Adejuyigbe, E., . . . Owen, A. (2015). Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study. Clin Infect Dis, 61(3), 453-463. doi:10.1093/cid/civ317The Application of Nanotechnology to Drug Delivery in Medicine (Chapter)
McDonald, T. O., Siccardi, M., Moss, D., Liptrott, N., Giardiello, M., Rannard, S., & Owen, A. (2015). The Application of Nanotechnology to Drug Delivery in Medicine. In Nanoengineering (pp. 173-223). Elsevier. doi:10.1016/b978-0-444-62747-6.00007-5Misoprostol-induced fever and genetic polymorphisms in drug transporters SLCO1B1 and ABCC4 in women of Latin American and European ancestry (Journal article)
Alfirevic, A., Durocher, J., Elati, A., Leon, W., Dickens, D., Raedisch, S., . . . Winikoff, B. (2015). Misoprostol-induced fever and genetic polymorphisms in drug transporters SLCO1B1 and ABCC4 in women of Latin American and European ancestry. PHARMACOGENOMICS, 16(9), 919-928. doi:10.2217/pgs.15.53Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions (Journal article)
Liptrott, N. J., Giardiello, M., Hunter, J. W., Tatham, L., Tidbury, L. R., Siccardi, M., . . . Owen, A. (2015). Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions. NANOMEDICINE, 10(9), 1407-1421. doi:10.2217/NNM.14.77Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS (Journal article)
Olagunju, A., Bolaji, O. O., Amara, A., Waitt, C., Else, L., Soyinka, J., . . . Khoo, S. (2015). Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(2), 555-561. doi:10.1093/jac/dku420Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults (Journal article)
Marzolini, C., Sabin, C., Raffi, F., Siccardi, M., Mussini, C., Launay, O., . . . Battegay, M. (2015). Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. AIDS, 29(2), 193-200. doi:10.1097/QAD.0000000000000530Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter (Journal article)
Moss, D. M., Liptrott, N. J., Siccardi, M., & Owen, A. (2015). Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter. FRONTIERS IN PHARMACOLOGY, 6. doi:10.3389/fphar.2015.00078Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine (Journal article)
Schipani, A., Back, D., Owen, A., Davies, G., Khoo, S., & Siccardi, M. (2015). Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine. CLINICAL PHARMACOKINETICS, 54(1), 107-116. doi:10.1007/s40262-014-0184-82014
CYP2B6 516G > T (rs3745274) and Smoking Status Are Associated With Efavirenz Plasma Concentration in a Serbian Cohort of HIV Patients (Journal article)
Olagunju, A., Siccardi, M., Amara, A., Jevtovic, D., Kusic, J., Owen, A., & Dragovic, G. (2014). CYP2B6 516G > T (rs3745274) and Smoking Status Are Associated With Efavirenz Plasma Concentration in a Serbian Cohort of HIV Patients. THERAPEUTIC DRUG MONITORING, 36(6), 734-738. doi:10.1097/FTD.0000000000000098A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication (Journal article)
Moss, D. M., Curley, P., Shone, A., Siccardi, M., & Owen, A. (2014). A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication. Journal of Antimicrobial Chemotherapy, 69(12), 3275-3281. doi:10.1093/jac/dku312A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication (Journal article)
Moss, D. M., Curley, P., Shone, A., Siccardi, M., & Owen, A. (2014). A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69(12), 3275-3281. doi:10.1093/jac/dku312Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV‐infected patients: a population PK approach (Journal article)
Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2014). Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV‐infected patients: a population PK approach. Journal of the International AIDS Society, 17(4S3). doi:10.7448/ias.17.4.19586Optimisation of Intramuscular Sustained Release-Nano-Formulations Using In Silico Modelling (Poster)
Rajoli, R. K. R., Back, D., Rannard, S., Owen, A., & Siccardi, M. (2014). Optimisation of Intramuscular Sustained Release-Nano-Formulations Using In Silico Modelling. Poster session presented at the meeting of Conference On Retroviruses And Opportunistic Infections. Boston, MA, USA.Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation (Journal article)
McDonald, T. O., Giardiello, M., Martin, P., Siccardi, M., Liptrott, N. J., Roberts, P., . . . Owen, A. (2014). Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation. Advanced Healthcare Materials, 3(3), 400-411. doi:10.1002/adhm.201300280CYP3A4*22 (c.522-191 C > T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults (Journal article)
Olagunju, A., Schipani, A., Siccardi, M., Egan, D., Khoo, S., Back, D., & Owen, A. (2014). CYP3A4*22 (c.522-191 C > T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. PHARMACOGENETICS AND GENOMICS, 24(9), 459-463. doi:10.1097/FPC.0000000000000073Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions (Journal article)
Liptrott, N., Giardiello, M., Hunter, J. W., Tatham, L., Tidbury, L. R., Siccardi, M., . . . Owen, A. (2014). Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions. Nanomedicine (London).Highlights of research at the University of Liverpool and activity of the British Society for Nanomedicine (Poster)
Curley, P., Liptrott, N., Tatham, L., Siccardi, M., & Owen, A. (2014). Highlights of research at the University of Liverpool and activity of the British Society for Nanomedicine. Poster session presented at the meeting of 7th CLINAM Conference and Exhibition. Basel, Switzerland.Multi-system investigation of the mechanisms for raltegravir association with intestinal tissue after oral administration (Poster)
Moss, D., Curley, P., Shone, A., Siccardi, M., & Owen, A. (2014). Multi-system investigation of the mechanisms for raltegravir association with intestinal tissue after oral administration. Poster session presented at the meeting of 21st Conference on Retroviruses and Opportunistic Infections. Boston, USA.Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling (Journal article)
Moss, D. M., & Siccardi, M. (2014). Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling. BRITISH JOURNAL OF PHARMACOLOGY, 171(17), 3963-3979. doi:10.1111/bph.12604Polymorphisms in SLC34A1 and ABCC2 genes are related with altered renal tubular function in HIV-positive patients receiving tenofovir (Conference Paper)
Alvarez, E., Owen, A., Martin Carbonero, L., Siccardi, M., Valencia, E., Moreno, V., . . . Rodriguez-Novoa, S. (2014). Polymorphisms in SLC34A1 and ABCC2 genes are related with altered renal tubular function in HIV-positive patients receiving tenofovir. In ANTIVIRAL THERAPY Vol. 19 (pp. A11). Retrieved from https://www.webofscience.com/Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach (Journal article)
Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2014). Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach. J Int AIDS Soc, 17(4 Supp), 19586.Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach. (Journal article)
Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2014). Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach.. Journal of the International AIDS Society, 17(4 Suppl 3), 19586. doi:10.7448/ias.17.4.19586The in vivo effects of solid drug nanoparticle and conventional efavirenz on anxiogenesis in rodents (Poster)
Curley, P., Giardiello, M., Liptrott, N., Martin, P., McDonald, T., Siccardi, M., . . . Owen, A. (2014). The in vivo effects of solid drug nanoparticle and conventional efavirenz on anxiogenesis in rodents. Poster session presented at the meeting of 21st Conference on Retroviruses and Opportunistic Infections. Boston, USA.2013
Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 In Vitro (Journal article)
Moss, D. M., Liptrott, N. J., Curley, P., Siccardi, M., Back, D. J., & Owen, A. (2013). Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 In Vitro. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(11), 5612-5618. doi:10.1128/AAC.01421-13Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective (Journal article)
Siccardi, M., Rajoli, R. K. R., Curley, P., Olagunju, A., Moss, D., & Owen, A. (2013). Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective. FUTURE VIROLOGY, 8(9), 871-890. doi:10.2217/fvl.13.67Predicting intestinal absorption of raltegravir using a population-based ADME simulation (Journal article)
Moss, D. M., Siccardi, M., Back, D. J., & Owen, A. (2013). Predicting intestinal absorption of raltegravir using a population-based ADME simulation. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 68(7), 1627-1634. doi:10.1093/jac/dkt084Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach (Journal article)
Siccardi, M., Marzolini, C., Seden, K., Almond, L., Kirov, A., Khoo, S., . . . Back, D. (2013). Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach. CLINICAL PHARMACOKINETICS, 52(7), 583-592. doi:10.1007/s40262-013-0056-7Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells (Journal article)
D'Avolio, A., Simiele, M., Calcagno, A., Siccardi, M., Larovere, G., Agati, S., . . . Bonora, S. (2013). Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 68(4), 907-910. doi:10.1093/jac/dks484Correlates of Efavirenz Exposure in Chilean Patients Affected With Human Immunodeficiency Virus Reveals a Novel Association With a Polymorphism in the Constitutive Androstane Receptor (Journal article)
Cortes, C. P., Siccardi, M., Chaikan, A., Owen, A., Zhang, G., & la Porte, C. J. L. (2013). Correlates of Efavirenz Exposure in Chilean Patients Affected With Human Immunodeficiency Virus Reveals a Novel Association With a Polymorphism in the Constitutive Androstane Receptor. THERAPEUTIC DRUG MONITORING, 35(1), 78-83. doi:10.1097/FTD.0b013e318274197eNanomedicines for HIV therapy. (Journal article)
Siccardi, M., Martin, P., McDonald, T. O., Liptrott, N. J., Giardiello, M., Rannard, S., & Owen, A. (2013). Nanomedicines for HIV therapy.. Therapeutic delivery, 4(2), 153-156. doi:10.4155/tde.12.156Enhanced Pharmacological Properties of Efavirenz Formulated as Solid Drug Nanoparticles (Conference Paper)
Martin, P., Liptrott, N., McDonald, T., Giardiello, M., Roberts, P., Curley, P., . . . Owen, A. (2013). Enhanced Pharmacological Properties of Efavirenz Formulated as Solid Drug Nanoparticles. In 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, USA.Investigation of the potential interactions of efavirenz and the GABAa receptor utilising an in silico approach (Poster)
Curley, P., Schipani, A., Siccardi, M., & Owen, A. (2013). Investigation of the potential interactions of efavirenz and the GABAa receptor utilising an in silico approach. Poster session presented at the meeting of Manchester Life Sciences PhD Conference. Manchester, UK.Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective (Journal article)
Siccardi, M., Rajoli, R. K. R., Curley, P., Olagunju, A., Moss, D., & Owen, A. (2013). Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective. Future Virology,, 8(9), 871-890.Prediction of Etravirine Pharmacogenetics using a Physiologically Based Pharmacokinetic approach (Conference Paper)
Siccardi, M., Olagunju, A., Curley, P., Hobson, J., Khoo, S., Back, D., & Owen, A. (2013). Prediction of Etravirine Pharmacogenetics using a Physiologically Based Pharmacokinetic approach. In 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, USA.Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz (Journal article)
Siccardi, M., Olagunju, A., Seden, K., Ebrahimjee, F., Rannard, S., Back, D., & Owen, A. (2013). Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz. In Silico Pharmacology, 1(4).Utilising In Vitro-In Vivo extrapolation to investigate efavirenz penetration into the central nervous system (Poster)
Curley, P., Martin, P., Liptrott, N., Back, D., Owen, A., & Siccardi, M. (2013). Utilising In Vitro-In Vivo extrapolation to investigate efavirenz penetration into the central nervous system. Poster session presented at the meeting of 14th International Workshop on Clinical Pharmacology of HIV Therapy. Netherlands.2012
Efavirenz in an obese HIV-infected patient - a report and an in vitro-in vivo extrapolation model indicate risk of underdosing (Journal article)
de Roche, M., Siccardi, M., Stoeckle, M., Livio, F., Back, D., Battegay, M., & Marzolini, C. (2012). Efavirenz in an obese HIV-infected patient - a report and an in vitro-in vivo extrapolation model indicate risk of underdosing. ANTIVIRAL THERAPY, 17(7), 1381-1384. doi:10.3851/IMP2107Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment (Journal article)
D'Avolio, A., Ciancio, A., Siccardi, M., Smedile, A., Simiele, M., Cusato, J., . . . Di Perri, G. (2012). Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. THERAPEUTIC DRUG MONITORING, 34(6), 722-728. doi:10.1097/FTD.0b013e318272e55aPharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an In Vitro-In Vivo Extrapolation Model (Journal article)
Siccardi, M., Almond, L., Schipani, A., Csajka, C., Marzolini, C., Wyen, C., . . . Back, D. (2012). Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an In Vitro-In Vivo Extrapolation Model. CLINICAL PHARMACOLOGY & THERAPEUTICS, 92(4), 494-502. doi:10.1038/clpt.2012.61Prophylactic Drug Monitoring of Itraconazole in an Oncohematological Pediatric Patient Population (Journal article)
Baietto, L., De Rosa, F. G., D'Avolio, A., Marra, C., Pace, S., Biasin, E., . . . Di Perri, G. (2012). Prophylactic Drug Monitoring of Itraconazole in an Oncohematological Pediatric Patient Population. THERAPEUTIC DRUG MONITORING, 34(5), 604-606. doi:10.1097/FTD.0b013e31826a701eDeterminants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics (Journal article)
Calcagno, A., Yilmaz, A., Cusato, J., Simiele, M., Bertucci, R., Siccardi, M., . . . Bonora, S. (2012). Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. AIDS, 26(12), 1529-1533. doi:10.1097/QAD.0b013e3283553619Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices (Journal article)
Calcagno, A., D'Avolio, A., Simiele, M., Cusato, J., Rostagno, R., Libanore, V., . . . Di Perri, G. (2012). Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 74(1), 134-140. doi:10.1111/j.1365-2125.2012.04163.xDivalent Metals and pH Alter Raltegravir Disposition In Vitro (Journal article)
Moss, D. M., Siccardi, M., Murphy, M., Piperakis, M. M., Khoo, S. H., Back, D. J., & Owen, A. (2012). Divalent Metals and pH Alter Raltegravir Disposition In Vitro. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(6), 3020-3026. doi:10.1128/AAC.06407-11Inosine Triphosphatase Polymorphisms and Ribavirin Pharmacokinetics as Determinants of Ribavirin-Associate Anemia in Patients Receiving Standard Anti-HCV Treatment (Journal article)
D'Avolio, A., Ciancio, A., Siccardi, M., Smedile, A., Baietto, L., Simiele, M., . . . Di Perri, G. (2012). Inosine Triphosphatase Polymorphisms and Ribavirin Pharmacokinetics as Determinants of Ribavirin-Associate Anemia in Patients Receiving Standard Anti-HCV Treatment. THERAPEUTIC DRUG MONITORING, 34(2), 165-170. doi:10.1097/FTD.0b013e31824bf778Intrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting (Journal article)
Siccardi, M., D'Avolio, A., Rodriguez-Novoa, S., Cuenca, L., Simiele, M., Baietto, L., . . . Di Perri, G. (2012). Intrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting. THERAPEUTIC DRUG MONITORING, 34(2), 232-235. doi:10.1097/FTD.0b013e31824aa50aOnce daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg (Journal article)
Okoli, C., Siccardi, M., Thomas-William, S., Dufty, N., Khonyongwa, K., Ainsworth, J., . . . Taylor, S. (2012). Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 67(3), 671-674. doi:10.1093/jac/dkr493Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study (Journal article)
Else, L. J., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(3), 1427-1433. doi:10.1128/AAC.05599-11Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS (Journal article)
Liptrott, N. J., Pushpakom, S., Wyen, C., Fätkenheuer, G., Hoffmann, C., Mauss, S., . . . Owen, A. (2012). Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenetics and Genomics, 22(1), 10-19. doi:10.1097/fpc.0b013e32834dd82eAssociation of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS (Journal article)
Liptrott, N. J., Pushpakom, S., Wyen, C., Faetkenheuer, G., Hoffmann, C., Mauss, S., . . . Owen, A. (2012). Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. PHARMACOGENETICS AND GENOMICS, 22(1), 10-19. doi:10.1097/FPC.0b013e32834dd82eInvestigation of the potential interactions of efavirenz with the GABAa receptor (Poster)
Curley, P., Schipani, A., Egan, D., Siccardi, M., Wyen, C., Fätkenheuer, G., & Owen, A. (2012). Investigation of the potential interactions of efavirenz with the GABAa receptor. Poster session presented at the meeting of British Pharmacology Society Winter Meeting. London, UK.Once daily maraviroc 300mg or 150mg OD in combination with ritonavir -boosted darunavir 800/100mg. (Journal article)
Okoli, C., Siccardi, M., Thomas-William, S., Dufty, N., Khonyongwa, K., Ainsworth, J., . . . Taylor, S. (2012). Once daily maraviroc 300mg or 150mg OD in combination with ritonavir -boosted darunavir 800/100mg.. Journal of Antimicrobial Chemotherapy, 67, 671-674.Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study (Journal article)
Else, L., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrob Agents Chemother, 56(3), 1427-1433.Prediction of drug-drug interactions between various antidepressants and ritonavir using a physiologically based pharmacokinetic model (Journal article)
Siccardi, M., Marzolini, C., Seden, K., Almond, L., Kirov, A., Khoo, S., . . . Back, D. (2012). Prediction of drug-drug interactions between various antidepressants and ritonavir using a physiologically based pharmacokinetic model. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 15, 60. doi:10.7448/IAS.15.6.18339Prophylactic drug monitoring of itraconazole in an oncohematological pediatric patient population (Journal article)
Baietto, L., De Rosa, F. G., D'Avolio, A., Marra, C., Pace, S., Biasin, E., . . . Di Perri, G. (2012). Prophylactic drug monitoring of itraconazole in an oncohematological pediatric patient population. Ther Drug Monit, 34(5), 604-606. doi:10.1097/FTD.0b013e31826a701e00007691-201210000-000202011
Influence of CYP2B6 and ABCB1 SNPs on Nevirapine Plasma Concentrations in Burundese HIV-positive Patients Using Dried Sample Spot Devices (Journal article)
Calcagno, A., D'Avolio, A., Simiele, M., Cusato, J., Rostagno, R., Libanore, V., . . . Di Perri, G. (2011). Influence of CYP2B6 and ABCB1 SNPs on Nevirapine Plasma Concentrations in Burundese HIV-positive Patients Using Dried Sample Spot Devices. British Journal of Clinical Pharmacology, no. doi:10.1111/j.1365-2125.2011.04163.xRibavirin Pharmacokinetics and Interleukin 28B Plus Cytochrome P450 27B1 Single-Nucleotide Polymorphisms as Predictors of Response to Pegylated Interferon/Ribavirin Treatment in Patients Infected with Hepatitis C Virus Genotype 1/4 (Journal article)
D'Avolio, A., Ciancio, A., Siccardi, M., Baietto, L., Simiele, M., Cariti, G., . . . Di Perri, G. (2011). Ribavirin Pharmacokinetics and Interleukin 28B Plus Cytochrome P450 27B1 Single-Nucleotide Polymorphisms as Predictors of Response to Pegylated Interferon/Ribavirin Treatment in Patients Infected with Hepatitis C Virus Genotype 1/4. HEPATOLOGY, 54(6), 2278-2279. doi:10.1002/hep.24636Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens (Journal article)
Wyen, C., Hendra, H., Siccardi, M., Platten, M., Jaeger, H., Harrer, T., . . . Owen, A. (2011). Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 66(9), 2092-2098. doi:10.1093/jac/dkr272Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients (Journal article)
Bonora, S., de Requena, D. G., D'Avolio, A., Calcagno, A., Tettoni, M., Siccardi, M., . . . Di Perri, G. (2011). Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. ANTIVIRAL THERAPY, 16(4), 499-504. doi:10.3851/IMP1802Ceftriaxone bone penetration in patients with septic non-union of the tibia (Journal article)
Garazzino, S., Aprato, A., Baietto, L., D'Avolio, A., Maiello, A., De Rosa, F. G., . . . Di Perri, G. (2011). Ceftriaxone bone penetration in patients with septic non-union of the tibia. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 15(6), E415-E421. doi:10.1016/j.ijid.2011.03.003Evaluation of the Mean Corpuscular Volume of Peripheral Blood Mononuclear Cells of HIV Patients by a Coulter Counter To Determine Intracellular Drug Concentrations (Journal article)
Simiele, M., D'Avolio, A., Baietto, L., Siccardi, M., Sciandra, M., Agati, S., . . . Di Perri, G. (2011). Evaluation of the Mean Corpuscular Volume of Peripheral Blood Mononuclear Cells of HIV Patients by a Coulter Counter To Determine Intracellular Drug Concentrations. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(6), 2976-2978. doi:10.1128/AAC.01236-10Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals (Journal article)
Schipani, A., Wyen, C., Mahungu, T., Hendra, H., Egan, D., Siccardi, M., . . . Back, D. J. (2011). Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 66(6), 1332-1339. doi:10.1093/jac/dkr087A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation (Journal article)
D'Avolio, A., Simiele, M., Siccardi, M., Baietto, L., Sciandra, M., Oddone, V., . . . Di Perri, G. (2011). A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 54(4), 779-788. doi:10.1016/j.jpba.2010.10.011Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir (Journal article)
Moss, D. M., Kwan, W. S., Liptrott, N. J., Smith, D. L., Siccardi, M., Khoo, S. H., . . . Owen, A. (2011). Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(2), 879-887. doi:10.1128/AAC.00623-10INTRACELLULAR ACCUMULATION OF RITONAVIR ASSOCIATED WITH DIFFERENT BOOSTED PIS (Conference Paper)
D'Avolio, A., Simiele, M., Siccardi, M., Baietto, L., Agati, S., Cusato, J., . . . Di Perri, G. (2011). INTRACELLULAR ACCUMULATION OF RITONAVIR ASSOCIATED WITH DIFFERENT BOOSTED PIS. In INFECTION Vol. 39 (pp. S24). Retrieved from https://www.webofscience.com/2010
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T > C polymorphism (Journal article)
Siccardi, M., D'Avolio, A., Nozza, S., Simiele, M., Baietto, L., Stefani, F. R., . . . Owen, A. (2010). Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T > C polymorphism. PHARMACOGENETICS AND GENOMICS, 20(12), 759-765. doi:10.1097/FPC.0b013e3283402efbPopulation Pharmacokinetic Modeling of the Association between 63396C -> T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance (Journal article)
Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., . . . Owen, A. (2010). Population Pharmacokinetic Modeling of the Association between 63396C -> T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(12), 5242-5250. doi:10.1128/AAC.00781-10Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance (Journal article)
Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., . . . Owen, A. (2010). Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. Antimicrobial Agents and Chemotherapy, 54(12), 5242-5250. doi:10.1128/aac.00781-10HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions (Journal article)
D'Avolio, A., Simiele, M., Siccardi, M., Baietto, L., Sciandra, M., Bonora, S., & Di Perri, G. (2010). HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 52(5), 774-780. doi:10.1016/j.jpba.2010.02.026Development, Validation, and Routine Application of a High-Performance Liquid Chromatography Method Coupled with a Single Mass Detector for Quantification of Itraconazole, Voriconazole, and Posaconazole in Human Plasma (Journal article)
Baietto, L., D'Avolio, A., Ventimiglia, G., De Rosa, F. G., Siccardi, M., Simiele, M., . . . Di Perri, G. (2010). Development, Validation, and Routine Application of a High-Performance Liquid Chromatography Method Coupled with a Single Mass Detector for Quantification of Itraconazole, Voriconazole, and Posaconazole in Human Plasma. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(8), 3408-3413. doi:10.1128/AAC.01807-09Raltegravir Penetration in Seminal Plasma of Healthy Volunteers (Journal article)
Calcagno, A., Bonora, S., D'Avolio, A., Siccardi, M., Simiele, M., Chiesa, M., . . . Di Perri, G. (2010). Raltegravir Penetration in Seminal Plasma of Healthy Volunteers. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(6), 2744-2745. doi:10.1128/AAC.00241-10Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds (Journal article)
Else, L., Watson, V., Tjia, J., Hughes, A., Siccardi, M., Khoo, S., & Back, D. (2010). Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 878(19), 1455-1465. doi:10.1016/j.jchromb.2010.03.036Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations (Journal article)
Rodriguez-Novoa, S., Labarga, P., D'Avolio, A., Barreiro, P., Albalate, M., Vispo, E., . . . Soriano, V. (2010). Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS, 24(7), 1064-1066. doi:10.1097/QAD.0b013e32833202e2A Validated High-Performance Liquid Chromatography-Ultraviolet Method for Quantification of the CCR5 Inhibitor Maraviroc in Plasma of HIV-Infected Patients (Journal article)
D'Avolio, A., Simiele, M., Baietto, L., Siccardi, M., Sciandra, M., Patanella, S., . . . Di Perri, G. (2010). A Validated High-Performance Liquid Chromatography-Ultraviolet Method for Quantification of the CCR5 Inhibitor Maraviroc in Plasma of HIV-Infected Patients. THERAPEUTIC DRUG MONITORING, 32(1), 86-92. doi:10.1097/FTD.0b013e3181cacbd0Altered plasma levels of nevirapine after commencing rifampicin-containing TB regimens in Malawi (Conference Paper)
Chaponda, M., Nyirenda, W., Watson, V., White, S., Van Oosterhout, J., Lalloo, D., . . . Khoo, S. (2010). Altered plasma levels of nevirapine after commencing rifampicin-containing TB regimens in Malawi. In HIV MEDICINE Vol. 11 (pp. 6). Retrieved from https://www.webofscience.com/Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma (Journal article)
Baietto, L., D'Avolio, A., De Rosa, F. G., Garazzino, S., Michelazzo, M., Ventimiglia, G., . . . Di Perri, G. (2010). Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 396(2), 791-798. doi:10.1007/s00216-009-3263-1Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism (Journal article)
Siccardi, M., D'Avolio, A., Nozza, S., Simiele, M., Baietto, L., Stefani, F. R., . . . Owen, A. (2010). Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. Pharmacogenet Genomics, 20(12), 759-765. doi:10.1097/FPC.0b013e3283402efb01213011-201012000-00004Population pharmacokinetics of unboosted atazanavir and influence of the pregnane -x- receptor PXR 63396C > T (Conference Paper)
Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Bonora, S., Davies, G., . . . Owen, A. (2010). Population pharmacokinetics of unboosted atazanavir and influence of the pregnane -x- receptor PXR 63396C > T. In HIV MEDICINE Vol. 11 (pp. 24). Retrieved from https://www.webofscience.com/2009
Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient (Journal article)
Di Biagio, A., Rosso, R., Siccardi, M., D'Avolio, A., Bonora, S., & Viscoli, C. (2009). Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 64(4), 874-875. doi:10.1093/jac/dkp269New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma (Journal article)
De Francia, S., D'Avolio, A., De Martino, F., Pirro, E., Baietto, L., Siccardi, M., . . . Di Perri, G. (2009). New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 877(18-19), 1721-1726. doi:10.1016/j.jchromb.2009.04.028Simultaneous Quantification of Linezolid, Rifampicin, Levofloxacin, and Moxifloxacin in Human Plasma Using High-Performance Liquid Chromatography With UV (Journal article)
Baietto, L., D'Avolio, A., De Rosa, F. G., Garazzino, S., Patanella, S., Siccardi, M., . . . Di Perri, G. (2009). Simultaneous Quantification of Linezolid, Rifampicin, Levofloxacin, and Moxifloxacin in Human Plasma Using High-Performance Liquid Chromatography With UV. THERAPEUTIC DRUG MONITORING, 31(1), 104-109. doi:10.1097/FTD.0b013e31819476faPHARMACOKINETICS AND PHARMACOGENETICS OF MARAVIROC IN THE CLINICAL SETTING (Conference Paper)
Siccardi, M., Bonora, S., Nozza, S., Castagna, A., D'Avolio, A., Michelazzo, M., . . . Di Perri, G. (2009). PHARMACOKINETICS AND PHARMACOGENETICS OF MARAVIROC IN THE CLINICAL SETTING. In INFECTION Vol. 37 (pp. 21). Retrieved from https://www.webofscience.com/PHARMACOKINETICS OF RALTEGRAVIR IN THE CLINICAL SETTING (Conference Paper)
Calcagno, A., Bonora, S., Nozza, S., Castagna, A., Ripamonti, D., D'Avolio, A., . . . Di Perri, G. (2009). PHARMACOKINETICS OF RALTEGRAVIR IN THE CLINICAL SETTING. In INFECTION Vol. 37 (pp. 69). Retrieved from https://www.webofscience.com/Validation of an ultra-sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for simultaneous determination of 11 anti-retroviral compounds (Conference Paper)
Else, L., Watson, V., Tjia, J., Siccardi, M., Khoo, S., & Back, D. (2009). Validation of an ultra-sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for simultaneous determination of 11 anti-retroviral compounds. In BRITISH JOURNAL OF CLINICAL PHARMACOLOGY Vol. 68 (pp. 276). Retrieved from https://www.webofscience.com/2008
An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients (Journal article)
D'Avolio, A., Baietto, L., Siccardi, M., Sciandra, M., Simiele, M., Oddone, V., . . . Di Perri, G. (2008). An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients. THERAPEUTIC DRUG MONITORING, 30(6), 662-669. doi:10.1097/FTD.0b013e318189596dGlycopeptide Bone Penetration in Patients with Septic Pseudoarthrosis of the Tibia (Journal article)
Garazzino, S., Aprato, A., Baietto, L., D'Avolio, A., Maiello, A., De Rosa, F. G., . . . Di Perri, G. (2008). Glycopeptide Bone Penetration in Patients with Septic Pseudoarthrosis of the Tibia. CLINICAL PHARMACOKINETICS, 47(12), 793-805. doi:10.2165/0003088-200847120-00004Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C -> T) with reduced concentrations of unboosted atazanavir (Journal article)
Siccardi, M., D'Avolio, A., Baietto, L., Gibbons, S., Sciandra, M., Colucci, D., . . . Owen, A. (2008). Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C -> T) with reduced concentrations of unboosted atazanavir. CLINICAL INFECTIOUS DISEASES, 47(9), 1222-1225. doi:10.1086/592304A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients (Journal article)
D'Avolio, A., Sciandra, M., Siccardi, M., Baietto, L., de Requena, D. G., Bonora, S., & Di Perri, G. (2008). A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients. JOURNAL OF CHROMATOGRAPHIC SCIENCE, 46(6), 524-528. doi:10.1093/chromsci/46.6.524The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon (Journal article)
Marucco, D. A., de Requena, D. G., Bonora, S., Tettoni, C., Bonasso, M., De Blasi, T., . . . Di Perri, G. (2008). The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 61(4), 919-924. doi:10.1093/jac/dkn013Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens (Journal article)
de Requena, D. G., Bonora, S., Calcagno, A., D'Avolio, A., Siccardi, M., Fontana, S., . . . Di Perri, G. (2008). Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 52(3), 1066-1071. doi:10.1128/AAC.01063-07A simple and fast method for quantification of ertapenem using meropenem as internal standard in human plasma in a clinical setting (Journal article)
D'Avolio, A., Baietto, L., De Rosa, F. G., Garazzino, S., Sciandra, M., Siccardi, M., . . . Di Perri, G. (2008). A simple and fast method for quantification of ertapenem using meropenem as internal standard in human plasma in a clinical setting. THERAPEUTIC DRUG MONITORING, 30(1), 90-94. doi:10.1097/FTD.0b013e31815f4f7eHPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients (vol 859, pg 234, 2007) (Journal article)
D'Avolio, A., Siccardi, M., Sciandra, M., Baietto, L., Bonora, S., Trentind, L., & Di Perri, G. (2008). HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients (vol 859, pg 234, 2007). JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 862(1-2), 265. doi:10.1016/j.jchromb.2007.11.015A simple and fast method for quantification of ertapenem using meropenem as internal standard in human plasma in a clinical setting (Journal article)
D'Avolio, A., Baietto, L., DeRosa, F. G., Garazzino, S., Sciandra, M., Siccardi, M., . . . Di Perri, G. (2008). A simple and fast method for quantification of ertapenem using meropenem as internal standard in human plasma in a clinical setting. Ther Drug Monit, 30(1), 90-94. doi:10.1097/FTD.0b013e31815f4f7e00007691-200802000-00014Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia (Journal article)
Garazzino, S., Aprato, A., Baietto, L., D'Avolio, A., Maiello, A., De Rosa, F. G., . . . Di Perri, G. (2008). Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia. Clin Pharmacokinet, 47(12), 793-805. doi:10.2165/0003088-200847120-00004471242007
Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject (Journal article)
Bonora, S., Calcagno, A., Fontana, S., D'Avolio, A., Siccardi, M., Gobbi, F., & Di Perri, G. (2007). Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject. CLINICAL INFECTIOUS DISEASES, 45(12), 1654-1655. doi:10.1086/523722HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients (Journal article)
D'Avolio, A., Siccardi, M., Sciandra, M., Lorena, B., Bonora, S., Trentini, L., & Di Perri, G. (2007). HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 859(2), 234-240. doi:10.1016/j.jchromb.2007.10.003A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method (Journal article)
D'Avolio, A., Sciandra, M., Siccardi, M., Baietto, L., de Requena, D. G., Bonora, S., & Di Perri, G. (2007). A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 848(2), 374-378. doi:10.1016/j.jchromb.2006.10.0302006
Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide (Journal article)
de Requena, D. G., Calcagno, A., Bonora, S., Ladetto, L., D'Avolio, A., Sciandra, M., . . . Di Perri, G. (2006). Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide. AIDS, 20(15), 1977-1979. doi:10.1097/01.aids.0000247121.19951.faValidation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients (Journal article)
D'Avolio, A., Ibanez, A., Sciandra, M., Siccardi, M., de Requena, D. G., Bonora, S., & Di Perri, G. (2006). Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 835(1-2), 127-130. doi:10.1016/j.jchromb.2006.03.019Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide (Journal article)
Gonzalez de Requena, D., Calcagno, A., Bonora, S., Ladetto, L., D'Avolio, A., Sciandra, M., . . . Di Perri, G. (2006). Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide. AIDS, 20(15), 1977-1979. doi:10.1097/01.aids.0000247121.19951.fa00002030-200610030-00012DOI: 10.1097/01.aids.0000247121.19951.fa00002030-200610030-00012